Beijing Lideman Biochemical Pharmaceutical Co., Ltd.
Board Statement on Transaction Parties Not Being Subject to Restrictions Under Article 12 of CSRC Supervision Guideline No. 7 — Supervision of Abnormal Trading in Major Asset Restructurings of Listed Companies, Regarding Participation in Any Major Asset Restructuring of Listed Companies
Beijing Lideman Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") intends to acquire 235,040,700 shares of Beijing PuraPharm Biotechnology Co., Ltd. (hereinafter referred to as "PuraPharm") (representing 61.50% of PuraPharm's issued share capital) from Hainan Baimai Investment Co., Ltd., Hainan PuraPharm Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "the Transaction") by way of cash payment.